Al­ler­gan CEO Brent Saun­ders takes a pric­ing pledge: Preda­to­ry prac­tices must end

Brent Saun­ders, Al­ler­gan

Caught in the lat­est tem­pest over dra­mat­ic price hikes for old ther­a­peu­tics, Al­ler­gan CEO Brent Saun­ders is swear­ing off the prac­tice, vow­ing to main­tain a fair pric­ing pol­i­cy that could well in­spire oth­ers in the busi­ness to fol­low suit.

This pledge in­cludes lim­it­ing Al­ler­gan’s an­nu­al price hikes to mod­est sin­gle-dig­it in­creas­es, and Saun­ders says Al­ler­gan will nev­er again jack up prices with­out a sig­nif­i­cant in­crease in costs as prod­ucts near the loss of patent pro­tec­tion, di­verg­ing from a stan­dard in­dus­try prac­tice he ad­mits the com­pa­ny has fol­lowed in the past.

In a blog post to­day, Saun­ders says:

Where we in­crease price on our brand­ed ther­a­peu­tic med­i­cines, we will take price in­creas­es no more than once per year and, when we do, they will be lim­it­ed to sin­gle-dig­it per­cent­age in­creas­es. Our ex­pec­ta­tion is that the over­all cost of our drugs, net of re­bates and dis­counts, will not in­crease by more than low-to-mid sin­gle dig­its per­cent­ages per year, slight­ly above the cur­rent an­nu­al rate of in­fla­tion.

There’s more. Saun­ders says that if the in­dus­try is ex­pect­ed to con­tin­ue to in­vest huge amounts in R&D, there has to be a way to prop­er­ly re­ward in­no­va­tion. Drug re­search, he adds, is done in a frag­ile ecosys­tem that will quick­ly col­lapse with­out ap­pro­pri­ate prices for new ther­a­pies.

“This ecosys­tem can quick­ly fall apart if it is not con­tin­u­al­ly nour­ished with the con­fi­dence that there will be a longer term op­por­tu­ni­ty for ap­pro­pri­ate re­turn on in­vest­ment in the long R&D jour­ney,” writes Saun­ders.

The in­dus­try has been quick to main­tain the same po­si­tion on R&D, not­ing that bio­phar­ma tra­di­tion­al­ly in­vests a rel­a­tive­ly large per­cent­age of its rev­enue in re­search. But Saun­ders com­mit­ment to a spe­cif­ic pric­ing pol­i­cy may take more than a few in­dus­try ex­ecs by sur­prise. Reg­u­lar, dou­ble-dig­it price hikes have be­come a main­stay in the in­dus­try, fol­lowed by all the big play­ers.

That prac­tice, though, has come un­der fire as My­lan, Valeant and Tur­ing have all come un­der fire in the last year for big price hikes on old­er prod­ucts that no one is in­vest­ing in. And the storm of protest has spurred Hillary Clin­ton to of­fer a new plan to rein in drug prices, mak­ing this a po­tent po­lit­i­cal is­sue in the run up to the fall elec­tion.

The in­dus­try lob­by­ing group BIO, mean­while, has de­cid­ed to counter the cur­rent shock­wave by launch­ing an ad­ver­tis­ing cam­paign aimed at high­light­ing the good drug de­vel­op­ers do. These kinds of feel-good cam­paigns about the pos­i­tive as­pects of new drugs, though, aren’t like­ly to even make a dent in the pub­lic rage fo­cused on price goug­ing. I asked BIO’s Jim Green­wood for a com­ment on Saun­der’s plan, but he de­clined to re­spond.

Aerial view of Genentech's campus in South San Francisco [Credit: Getty]

Genen­tech sub­mits a big plan to ex­pand its South San Fran­cis­co foot­print

The sign is still there, a quaint reminder of whitewashed concrete not 5 miles from Genentech’s sprawling, chrome-and-glass campus: South Francisco The Industrial City. 

The city keeps the old sign, first erected in 1923, as a tourist site and a kind of civic memento to the days it packed meat, milled lumber and burned enough steel to earn the moniker “Smokestack of the Peninsula.” But the real indication of where you are and how much has changed both in San Francisco and in the global economy since a couple researchers and investors rented out an empty warehouse 40 years ago comes in a far smaller blue sign, resembling a Rotary Club post, off the highway: South San Francisco, The Birthplace of Biotech.

Here comes the oral GLP-1 drug for di­a­betes — but No­vo Nordisk is­n't dis­clos­ing Ry­bel­sus price just yet

Novo Nordisk’s priority review voucher on oral semaglutide has paid off. The FDA approval for the GLP-1 drug hit late Friday morning, around six months after the NDA filing.

Rybelsus will be the first GLP-1 pill to enter the type 2 diabetes market — a compelling offering that analysts have pegged as a blockbuster drug with sales estimates ranging from $2 billion to $5 billion.

Ozempic, the once-weekly injectable formulation of semaglutide, brought in around $552 million (DKK 3.75 billion) in the first half of 2019.

As Nas­daq en­rolls the fi­nal batch of 2019 IPOs, how have the num­bers com­pared to past years?

IGM Biosciences’ upsized IPO haul, coming after SpringWorks’ sizable public debut, has revved up some momentum for the last rush of biotech IPOs in 2019.

With 39 new listings on the books and roughly two more months to go before winding down, Nasdaq’s head of healthcare listings Jordan Saxe sees the exchange marking 50 to 60 biopharma IPOs for the year.

“December 15 is usually the last possible day that companies will price,” he said, as companies get ready for business talks at the annual JP Morgan Healthcare Conference in January.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 60,200+ biopharma pros reading Endpoints daily — and it's free.

Oxitec biologist releases genetically modified mosquitoes in Piracicaba, Brazil in 2016 [credit: Getty Images]

In­trex­on unit push­es back against claims its GM mos­qui­toes are mak­ing dis­ease-friend­ly mu­tants

When the hysteria of Zika transmission sprang into the American zeitgeist a few years ago, UK-based Oxitec was already field-testing its male Aedes aegypti mosquito, crafted to possess a gene engineered to obliterate its progeny long before maturation.

But when a group of independent scientists evaluated the impact of the release of these genetically-modified mosquitoes in a trial conducted by Oxitec in Brazil between 2013 and 2015, they found that some of the offspring had managed to survive — prompting them to speculate what impact the survivors could have on disease transmission and/or insecticide resistance.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 60,200+ biopharma pros reading Endpoints daily — and it's free.

[via AP Images]

Pur­due threat­ens to walk away from set­tle­ment, asks to pay em­ploy­ees mil­lions in bonus­es

There are two updates on the lawsuit against Purdue Pharma over its role in fueling the opioid epidemic, as the Sackler family threatens to walk away from their pledge to pay out $3 billion if a bankruptcy judge does not stop outstanding state lawsuits against them. At the same time, the company has asked permission to pay millions in bonuses to select employees.

Purdue filed for chapter 11 bankruptcy this week as part of its signed resolution to over 2,000 lawsuits. The deal would see the Sackler family that owns Purdue give $3 billion from their personal wealth and the company turned into a trust committed to curbing and reversing overdoses.

David Grainger [file photo]

'Dis­con­nect the bas­tard­s' — one biotech's plan to break can­cer cell­s' uni­fied de­fens­es

Chemotherapy and radiotherapy are the current gladiators of cancer treatment, but they come with well-known limitations and side-effects. The emergence of immunotherapy — a ferocious new titan in oncologist’s toolbox — takes the brakes off the immune system to kill cancer cells with remarkable success in some cases, but the approach is not always effective. What makes certain forms of cancer so resilient? Scientists may have finally pieced together a tantalizing piece of the puzzle, and a new biotech is banking on a new approach to fill the gap.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 60,200+ biopharma pros reading Endpoints daily — and it's free.

A fa­vorite in Alex­ion’s C-suite is leav­ing, and some mighty sur­prised an­a­lysts aren’t the least bit hap­py about it

Analysts hate to lose a biotech CFO they’ve come to trust and admire — especially if they’re being blindsided by a surprise exit.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 60,200+ biopharma pros reading Endpoints daily — and it's free.

Scott Gottlieb, AP Images

Scott Got­tlieb is once again join­ing a team that en­joyed good times at the FDA un­der his high-en­er­gy stint at the helm

Right after jumping on Michael Milken’s FasterCures board on Monday, the newly departed FDA commissioner is back today with news about another life sciences board post that gives him a ringside chair to cheer on a lead player in the real-world evidence movement — one with very close ties to the FDA.

Aetion is reporting this morning that Gottlieb is joining their board, a group that includes Mohamad Makhzoumi, a general partner at New Enterprise Associates, where Gottlieb returned after stepping out of his role at the FDA 2 years after he started.

Gottlieb — one of the best connected execs in biopharma — knows this company well. As head of FDA he championed the use of real-world evidence to help guide drug developers and the agency in gaining greater efficiencies, which helped set up Aetion as a high-profile player in the game.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 60,200+ biopharma pros reading Endpoints daily — and it's free.

Tower Bridge in London [Shutterstock]

#UK­BIO19: Join GSK’s Hal Bar­ron and a group of top biotech ex­ecs for our 2nd an­nu­al biotech sum­mit in Lon­don

Over the past 10 years I’ve made a point of getting to know the Golden Triangle and the special role the UK biopharma industry plays there in drug development. The concentration of world class research institutes, some of the most accomplished scientists I’ve ever seen at work and a rising tide of global investment cash leaves an impression that there’s much, much more to come as biotech hubs are birthed and nurtured.